AAR INAUGURAL MTG OF BIOL WARFARE AD HOC WKG GROUP

File: 120396_sep96_decls90_0003.txt
Page: 0003
Total Pages: 8

Subject: AAR INAUGURAL MTG OF BIOL WARFARE AD HOC WKG GROUP              

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003203

Folder Title: AAR  INAUGURAL MEETING                                                                          

Document Number:          1

Folder SEQ  #:        211



                                    troFirTUNCLASSIFIED
                                    OL

          a.       Discussion on Botulinum

                   (1) (U) Incubation period from 3 to 36 hours.
          Initial symptoms include generalized weakness, lassitude and
          dizziness; neurological symptoms usually are present initially
          or early in disease; relatively easy to diagnosis clinically,
          however, routine laboratory findings are of no value in the
          diagnosis.

                   (2)      Pre- and post exposure prophylaxis and
          treatment was discussed. A pentavalent toxoid (A, B, C, D, E)
          given as a pre-exposure vaccine has been produced (under IND).
          Only limited quantities currently available.    It may be
          possible to increase production; however, large scale
          production may take up to six months. Limited data suggests
          that limited and transient antitoxin levels are induced after 3
          injections. The immune response to 1 or 2 doses of vaccine is
          being researched.   A human pentavalent antitoxin given
          pre-exposure has been produced and is available in very limited
          quantities (under IND). Two other products given
          post-exposure, equine trivalent (A, B, E,) commercially
          produced by Connaught, and a equine heptavalent antitoxin (A,
          B, C, D, E, P, and G) (no IND) are also available. The
          heptavalent antitoxin is the only product available in the
          treatment of the "F" toxin which AFMIC reported that Iraq
          possessed.

                 (3) (U) Supply of available vaccine (see 7B).

                 (4) (U) Immunization schedule. The currently
          recommended 5 dose schedule is at 0, 14, 84, and 365 days.

          7. @    RECOMMENDATIONS:

              a. @    Immunization of total force at risk (triservice)
          against anthrax, beginning with individuals most at risk.
ses of Anthrax vaccine until
          more vaccine becomes available. No recommendations were made
          regarding the use of pentavalent toxoid at the present time.

              b. @    Proceed with procurement of an
          doses of Anthrax vaccine to suDDlement the


          doses in 1-2 months and an
          However, as the same company produces both the Anthrax vaccine
          and the pentavalent toxoid, there may be some problems with
          both items being manufactured simultaneously at these levels.
          This issue is being researched.

              c. (U) Establish a permanent O'Task Force on Biological
          Warfare Issues."



                                ornnr,r UNCLASSIFIED
                                %)Lt#FILI

Document 8 f:/Week-36/BX003203/AAR INAUGURAL MEETING/aar inaugural mtg of biol warfare ad hoc wkg gro:11259610134130
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = AAR INAUGURAL MEETING
Folder Seq # = 211
Subject = AAR INAUGURAL MTG OF BIOL WARFARE AD HOC WKG GRO
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 25-NOV-1996